HUM · Humana Inc.

The thesis

Humana's 2027 Star Ratings put 95% of its Medicare Advantage members in plans rated 4 stars or higher, up from about 20% for 2026. That outcome sets up the quality-bonus revenue that 2028 margin recovery depends on. The 6 November 2026 third-quarter report now decides whether 2026 medical costs stay inside guidance while that revenue arrives.

The ratings settled the question this note was built around. The Centers for Medicare & Medicaid Services (CMS) released them on 8 October, and Healthcare Dive reported the shares rose almost 13% in after-hours trading that day. The earlier version of this note asked for an adjusted close above the $409.80 52-week high before any close below $365. The 13 October adjusted close of $420.38 meets that condition.

The narrative is accelerating again: between 9 October and 13 October, Barclays, Oppenheimer, Raymond James, UBS, Truist and Mizuho all raised price targets, and Raymond James upgraded the shares. Two more pieces of company news followed. On 13 October, Humana announced a CenterWell clinic joint venture with BlackRock and reaffirmed its 2026 earnings floor.

Bullish and bearish views on Humana Inc.

The bull case on Humana Inc. (HUM), in brief: Ratings rebounded to near the 2024 peak. The bear case: Ratings revenue arrives in 2028.

Bull case

• Ratings rebounded to near the 2024 peak. Humana said on 9 October 2026 that 95% of its Medicare Advantage members are in 4-star-or-better plans for 2027 and 42% are in 4.5-star plans. Eighteen contracts earned 4 stars or more, six of them 4.5 stars. Humana release
• Humana gained while the industry slipped. Healthcare Dive reported on 9 October 2026 that 37% of Medicare Advantage drug plans earned 4 stars or more for 2027, down from 44%, and the average rating fell to 3.99 from 4.01. UnitedHealth, CVS, Elevance and Centene had fewer members in 4-star plans. Healthcare Dive
• The 2028 revenue lift is large. TD Cowen's Ryan Langston estimated the recovery could bring Humana "$3 billion or more in extra revenue in 2028," according to the same 9 October Healthcare Dive report.
• The clinic deal cuts a liability. In an 13 October 2026 Form 8-K, Humana said funds managed by HPS, part of BlackRock, will buy Welsh, Carson, Anderson & Stowe's roughly $2.8 billion stake in nearly 150 CenterWell clinics. The new venture has no put option, so Humana expects much lower related liabilities. It also reaffirmed 2026 adjusted EPS of at least $9.00. Form 8-K
• Analysts moved targets well above the price. Barclays raised its target from $515 to $582 on 9 October. Oppenheimer went to $525 and Raymond James upgraded to Outperform with a $520 target on 12 October. All three sit above the $433.50 52-week high.

Bear case

• Ratings revenue arrives in 2028. Star Ratings released in October 2026 set quality-bonus payments for plan year 2028. The 2026 and 2027 plan years get no help from them, and Humana has published no 2027 earnings guidance.
• The third quarter is guided to a loss. Humana's 29 July 2026 prepared remarks guided to an adjusted loss of about $1.00 per share in the third quarter. They also called for a third-quarter benefit ratio slightly above 94% and a full-year ratio of 92.75% plus or minus 25 basis points. Any cost overrun lands on the 6 November report.
• Neutral ratings sit near the price. On 12 October, Truist kept a Hold rating with a $475 target and UBS kept Neutral at $495. Both firms see limited upside even after the ratings news.
• The 2027 enrollment outcome is unknown. Medicare open enrollment runs from 15 October to 7 December 2026. Humana's membership and the mix of members it wins for 2027 will not be disclosed until after the window closes.

Price setup

The shares closed at $420.38 on 13 October 2026, on split- and dividend-adjusted daily closes. That is 3.0% below the $433.50 52-week high and up 8.8% over three months. The 14-day relative strength index (RSI) reads 66, short of the 70 level usually read as overbought.

The shares gapped above the $409.80 prior 52-week high on the ratings news. That level is now the nearest reference below the price. Before the release, the shares closed at $389.63 on 28 September and $381.57 on 30 September. A return to that range would undo the ratings gain.

The signs of crowding are clear. Six firms changed targets within three trading days. Benzinga flagged large options trades in Humana on 2 September and 11 September. The 6 November earnings date falls inside the next four weeks.

Catalysts, next 30 days

• 15 October 2026 — Medicare open enrollment opens. It runs through 7 December and sets 2027 membership. For the first time since 2024, Humana markets most of its plans at 4 stars or higher.
• 6 November 2026 — Third-quarter 2026 report, 8:00 a.m. ET call. The report tests the guided adjusted loss of about $1.00 per share, the 92.75% full-year benefit-ratio range and the $9.00 adjusted EPS floor. Management may also comment on how the ratings feed into 2027 and 2028.
• By 31 December 2026 (est.) — BlackRock clinic venture closes. Humana expects the deal to close in the fourth quarter. Closing removes the put-option liability tied to the existing clinic ventures.

What would change the view

A cost problem would break the case. If the 6 November report guides the full-year benefit ratio above 93.0%, the top of the current range, the case fails. A cut to the $9.00 adjusted EPS floor would also end it, because better 2028 revenue matters less if the 2026 cost base is moving the wrong way.

A policy shock would weaken it too. Any CMS change that reduces the value of quality-bonus payments or Medicare Advantage risk-adjustment revenue before 2028 would undercut the TD Cowen revenue estimate the case relies on. On price, the case is broken by a daily close below $390, which would put the shares back at their late-September closes from before the ratings release.

What it trades with

Humana moves with UnitedHealth, CVS Health, Elevance and Centene on CMS rate notices, policy headlines and medical-cost trend data. Those shared shocks still apply. The 2027 ratings split the group, though. Healthcare Dive reported on 9 October that the large peers lost 4-star membership while Humana gained. That makes Humana's 2028 revenue outlook more company-specific than it was a year ago. Alignment Healthcare was the biggest loser: 25% of its members are in 4-star plans for 2027, down from 98%.